drugset
drugset / Trial / NCT01874522

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

NCT01874522 ↗

Phase 1 Completed 46 enrolled Taiho Oncology, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.

Timeline

Start
2013-07
Primary completion
2015-08
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject FTD Unknown — Oral
Subject TPI Unknown — Oral

Indications

No indication recorded.